Humana (NYSE:HUM) Receives "Outperform" Rating from Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Humana (NYSE:HUM - Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $283.00 price objective on the insurance provider's stock.

Several other research firms also recently weighed in on HUM. Wells Fargo & Company lowered their price target on shares of Humana from $387.00 to $290.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Piper Sandler increased their price objective on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday. Truist Financial upped their price target on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a report on Monday, January 6th. Finally, Barclays increased their price target on Humana from $253.00 to $255.00 and gave the company an "equal weight" rating in a report on Wednesday, January 22nd. Nineteen research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $293.05.

Humana Price Performance

Shares of Humana stock traded up $0.73 on Wednesday, hitting $253.61. 2,386,047 shares of the company traded hands, compared to its average volume of 1,515,752. Humana has a 12-month low of $213.31 and a 12-month high of $406.46. The firm's 50-day simple moving average is $271.27 and its 200 day simple moving average is $293.44. The company has a market cap of $30.54 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.11 and a beta of 0.56. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. Analysts expect that Humana will post 16.11 earnings per share for the current fiscal year.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.32% of the company's stock.

Institutional Investors Weigh In On Humana

Several large investors have recently made changes to their positions in the company. Creative Financial Designs Inc. ADV grew its holdings in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in Humana during the third quarter valued at $31,000. Your Advocates Ltd. LLP grew its stake in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares in the last quarter. FPC Investment Advisory Inc. bought a new stake in shares of Humana in the 4th quarter worth about $27,000. Finally, Centricity Wealth Management LLC purchased a new stake in shares of Humana during the 4th quarter valued at about $30,000. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.